Iptacopan (Fabhalta) is the first medicine approved for C3G in adults to lower protein in the urine. Fabhalta is a medicine that blocks factor B of the alternative complement system, which is ...

Your treatment will depend on how many symptoms you have and how severe they are. Fabhalta is a medicine that works to block factor B of the complement system, which is part of your immune system.

have recommended reimbursement of Fabhalta in the treatment of adult patients with PNH who have an inadequate response to, or are intolerant of, a C5 inhibitor 5,6 Novartis Pharmaceuticals Canada ...

Fabhalta (iptacopan) is a prescription drug that’s used to treat a rare type of kidney disease and a rare blood disorder. Fabhalta comes as an oral capsule that’s typically taken twice per day.

EAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of ...

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway. APPULSE-PNH is a phase IIIB multicenter, ...

Novartis (NYSE:NVS) reported positive Phase 3b data from a study of its drug Fabhalta for the treatment of the rare blood disorder paroxysmal nocturnal hemoglobinuria, or PNH. The study ...

East Hanover, N.J., Aug. 7, 2024 /PRNewswire/ -- Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in ...

Findings from the APPEAR-C3G trial showed a 35% reduction in 24-hour UPCR from baseline (primary endpoint) in the iptacopan group compared with the placebo group. The Food and Drug Administration ...

Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs ...